
electroCore, Inc. (NASDAQ:ECOR – Free Report) – Research analysts at Brookline Cap M issued their FY2025 earnings per share (EPS) estimates for electroCore in a note issued to investors on Tuesday, February 3rd. Brookline Cap M analyst F. Ahmed anticipates that the company will post earnings of ($1.70) per share for the year. Brookline Cap M currently has a “Strong-Buy” rating on the stock. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. Brookline Cap M also issued estimates for electroCore’s Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.33) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.53) EPS.
electroCore (NASDAQ:ECOR – Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.07). The business had revenue of $8.69 million during the quarter, compared to analysts’ expectations of $7.84 million. electroCore had a negative return on equity of 447.87% and a negative net margin of 47.46%.
Check Out Our Latest Stock Analysis on ECOR
electroCore Stock Up 7.5%
ECOR opened at $5.45 on Friday. The stock has a market capitalization of $43.60 million, a price-to-earnings ratio of -3.19 and a beta of 0.48. The firm has a 50 day moving average price of $5.59 and a 200-day moving average price of $5.43. electroCore has a twelve month low of $4.16 and a twelve month high of $19.49.
Institutional Trading of electroCore
Institutional investors and hedge funds have recently bought and sold shares of the stock. International Assets Investment Management LLC grew its position in shares of electroCore by 65.7% during the second quarter. International Assets Investment Management LLC now owns 77,020 shares of the company’s stock valued at $407,000 after purchasing an additional 30,550 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in electroCore during the 1st quarter valued at approximately $153,000. Jane Street Group LLC grew its holdings in electroCore by 114.4% during the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock valued at $246,000 after buying an additional 19,599 shares in the last quarter. NewEdge Advisors LLC increased its stake in electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock worth $1,083,000 after acquiring an additional 145,047 shares during the last quarter. Finally, Tejara Capital Ltd purchased a new stake in shares of electroCore during the 4th quarter worth approximately $450,000. 26.74% of the stock is currently owned by institutional investors.
Trending Headlines about electroCore
Here are the key news stories impacting electroCore this week:
- Positive Sentiment: Brookline Capital Management upgraded ECOR to a “Strong-Buy” and published new estimates that point toward improving profitability — forecasting FY2026 EPS of ($0.53) and a near-breakeven Q4 2026 EPS of ($0.01), which investors may view as a catalyst for the stock. Zacks Upgrade
- Neutral Sentiment: Brookline released a detailed quarter-by-quarter EPS schedule (Q4 2025: ($0.39); Q1 2026: ($0.33); Q2 2026: ($0.12); Q3 2026: ($0.08); Q4 2026: ($0.01)) giving investors a roadmap for when improvement is expected, but these are analyst projections rather than company guidance. MarketBeat Estimates
- Negative Sentiment: Despite the upgrade, Brookline still models a sizable loss for FY2025 (forecast: ($1.70) EPS), which is worse than the current consensus full-year estimate of ($1.49) — a reminder that near-term profitability and cash flow remain risk factors. MarketBeat Estimates
About electroCore
electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.
The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.
Further Reading
- Five stocks we like better than electroCore
- NEW LAW: Congress Approves Setup For Digital Dollar?
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- What a Former CIA Agent Knows About the Coming Collapse
- Trade this between 9:30 and 10:45 am EST
- When to buy gold (mathematically)
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
